Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation

Transplantation

Volumn 86, Issue 12, 2008, Pages 1771-1776

  Aliabadi, Arezu Z ^a   Mahr, Stephane ^a   Dunkler, Daniela ^a   Grömmer, Martina ^a   Zimpfer, Daniel ^a   Wolner, Ernst ^a   Grimm, Michael ^a   Zuckermann, Andreas O ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hyperlipidemia; Myopathy; Sirolimus; Statins

Indexed keywords

ASPARTATE AMMONIA LYASE; ATORVASTATIN; CHOLESTEROL; CYCLOSPORIN A; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; RAPAMYCIN; SIMVASTATIN; STEROID; TRANSFERASE; TRIACYLGLYCEROL; CORTICOSTEROID; CYCLOSPORIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PYRROLE DERIVATIVE;

ACNE; ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CORONARY ARTERY OBSTRUCTION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER TOXICITY; LOW DRUG DOSE; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOUTH ULCER; MYOPATHY; MYOSITIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; SKIN TUMOR; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; DYSLIPIDEMIA; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SAFETY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; CHOLESTEROL; CYCLOSPORINE; DYSLIPIDEMIAS; FEMALE; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRAVASTATIN; PYRROLES; SAFETY; SIROLIMUS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 58849117190     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181910eb2     Document Type: Article

References (39)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth of- ficial adult heart transplantation report-2007. J Heart Lung Transplant 2007; 26: 869.
2. Gao SZ, Schroederr JS, Alderman EL, et al. Clinical and laboratory correlates of accelerated coronary disease in cardiac transplant patients. Circulation 1987; 76: 56.
3. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 2006; 25: 1063.
4. Zuckermann A, Ploner M, Czerny M, et al. Low incidence of graft arteriosclerosis after cardiac transplantation: Risk factor analysis for patients with induction therapy. Transplant Proc 2002; 34: 1869.
5. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
6. Wenke K, Meiser B, Thiery J, et al. Simvastatin early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93.
7. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatinand pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40: 1809.
8. Keogh A, McDonald P, Kaan A, et al. Efficacy and safety vs. simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529.
9. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24: 1736.
10. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681.
11. Biggs MJ, Bonser RS, Cram R. Localized rhabdomyolysis after exertion in a cardiac transplant recipient on statin therapy. J Heart Lung Transplant 2005; 25: 356.
12. Rodiguez JA, Crespo-Leiro MG, Paniagua MJ,etal. Rhabdomyolysis in heart transplant patients onHMG-CoA reductase inhibitors and cyclo-sporine. Transplant Proc 1999; 31: 2522.
13. Zimmermann JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS Journal 2004; 6: 1.
14. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immnosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8: 854.
15. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694.
16. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
17. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568.
18. Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in cal-cineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24: 2129.
19. Jones PH, Davidson MH, Stein EA,et alComparison ofthe efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial) Am J Cardiol 2003; 92: 152.
20. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582.
21. Kendrach MG, Kelly-FreemanA.Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004; 38: 1286.
22. Raichlin E, Bae JB, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopa-thy after cardiac transplantation. Circulation 2007; 116: 2726.
23. ShepardJ,Cobbe SM, FordI, etal. Preventionof coronary heart disease with pravastatin in men with hypercholersterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995; 333: 1301.
24. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Prtotection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet 2003; 361: 2005.
25. McGiffen DC, SavunenT,Kirklin JK,etal. Cardiac transplant coronary disease. A multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thoac Cardiovasc Surg 1995; 109: 1081.
26. Carrier M, Rivard M, Kostuk W, et al. The Canadian Study of Cardiac Transplantation. Atherosclerosis. Invstigators of the CASCADE Study. Can J Cardiol 1999; 15: 1337.
27. Bilchik KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004; 148: 200.
28. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335: 1001.
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: A randomized placebo controlled trial.Lancet 2002; 360: 7.
30. See VY, Denofrio D, Goldberg L, et al. Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol 2003; 92: 11.
31. Chin C, Lukito SS, Shek J, et al. Prevention of pediatric graft coronary artery disease: Atorvastatin. Pediatr Transpant 2008; 12: 442.
32. Weis M, Pehlivanli S, Meiser B, et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38: 814.
33. Mach F. Statins as immunmodulators. Transpl Immunol 2002; 9: 197.
34. Katznelson S, Wang XM, Chia D, et al. The inhibitory effects of prav-astatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998; 17: 335.
35. Magnani G, Carinci V, Magelli C, et al. Role of statins in the management of dyslipidemia after cardiac transplant: Randomized controlled trial comparing the efficacy and safety of atorvastatin with pravastatin. J Heart Lung Transplant 2000; 19: 710.
36. Patel DN, Pagani FD, Koelling TM, et al. Safety and efficacy of atorva-statin in heart transplant reciepients. J Heart Lung Transplant 2002; 21: 204.
37. CelikS, DoeschA,Erbel C, etal. Beneficial effect of Omega-3 fatty acids on sirolimus- or everolimus- induced hyertriglyceridemia in heart transplant recipients. Transplantation 2008; 86: 245.
38. Grigioni F, Carigi S, Potena L, et al. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc 2006; 38: 1507.
39. Kovarik JM, Hartmann S, Hubert M, et al. Pharmakokinetic and phar-makodynamic assessmentsofHMG-Coa reductase inhibitors when coadminitered with everolimus. J Clin Pharmacol 2002; 42: 222.